https://www.selleckchem.com/pr....oducts/filgotinib.ht
4% had been provided the opportunity in the past year. Conclusions This study identifies health-care priorities and concerns for Americans with MS. © The Author(s) 2018.Background The study design and nature of oncology phase 1 clinical trials create a uniquely vulnerable patient population yet little research has been conducted to identify the added burden these trials create for both cancer patients and their caregiver(s). Objective Examining the perceptions and needs of patients and their caregivers participating in phase 1 oncolo
Beğen
Yorum Yap
Paylaş
